Anti-inflammatory effects of selective glucocorticoid receptor modulators are partially dependent on up-regulation of dual specificity phosphatase 1

British Journal of Pharmacology

Volumn 165, Issue 4 B, 2012, Pages 1124-1136

  Joanny, Eugénie ^a   Ding, Qize ^a   Gong, Leyi ^b   Kong, Philip ^a   Saklatvala, Jeremy ^a   Clark, Andrew R ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ROCHE BIOSCIENCE   (United States)

Author keywords

anti inflammatory drugs; gene transcription; immunopharmacology; inflammation; nuclear receptors; steroids neurosteroids

Indexed keywords

5 ALLYL 1,2 DIHYDRO 10 METHOXY 2,2,4 TRIMETHYL 5H 1 BENZOPYRANO[3,4 F]QUINOLINE; ANTIINFLAMMATORY AGENT; CPD 1; CPD 2; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; LGD 5552; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; PHOSPHOPROTEIN PHOSPHATASE 1; UNCLASSIFIED DRUG; ZK 218348; ZK 245186;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL TYPE; CONTROLLED STUDY; DENSITOMETRY; DRUG STRUCTURE; ENZYME SPECIFICITY; FEMALE; GENE PRODUCT; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BENZOFURANS; BENZOXAZINES; BONE MARROW CELLS; CELL LINE; CELL LINE, TUMOR; CYCLOOXYGENASE 2; CYTOKINES; DEXAMETHASONE; DUAL SPECIFICITY PHOSPHATASE 1; GLUCOCORTICOIDS; HELA CELLS; HUMANS; MACROPHAGES; MICE; MICE, KNOCKOUT; NF-KAPPA B; PENTANOLS; QUINOLINES; RECEPTORS, GLUCOCORTICOID; RNA, MESSENGER;

EID: 84856346550     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01574.x     Document Type: Article

References (65)

1. Abraham SM, Clark AR, (2006). Dual-specificity phosphatase 1: a critical regulator of innate immune responses. Biochem Soc Trans 34: 1018-1023. (Pubitemid 46768980)
2. Abraham SM, Lawrence T, Kleiman A, Warden P, Medghalchi M, Tuckermann J, et al,. (2006). Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. J Exp Med 203: 1883-1889. (Pubitemid 44188463)
3. Barnes PJ, (2006). Corticosteroids: the drugs to beat. Eur J Pharmacol 533: 2-14. (Pubitemid 43340000)
4. Beck IM, Vanden Berghe W, Vermeulen L, Yamamoto KR, Haegeman G, De Bosscher K, (2009). Crosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatases. Endocr Rev 30: 830-882.
5. Berlin M, (2010). Recent advances in the development of novel glucocorticoid receptor modulators. Expert Opin Ther Pat 20: 855-873.
6. Bladh LG, Johansson-Haque K, Rafter I, Nilsson S, Okret S, (2009). Inhibition of extracellular signal-regulated kinase (ERK) signaling participates in repression of nuclear factor (NF)-kappaB activity by glucocorticoids. Biochim Biophys Acta 1793: 439-446.
7. Cavet ME, Harrington KL, Ward KW, Zhang JZ, (2010). Mapracorat, a novel selective glucocorticoid receptor agonist, inhibits hyperosmolar-induced cytokine release and MAPK pathways in human corneal epithelial cells. Mol Vis 16: 1791-1800.
8. Chen W, Rogatsky I, Garabedian MJ, (2006). MEDI14 and MED1 differentially regulate target-specific gene activation by the glucocorticoid receptor. Mol Endoncrinol 20: 560-572. (Pubitemid 43291208)
9. Chivers JE, Gong W, King EM, Seybold J, Mak JC, Donnelly LE, et al,. (2006). Analysis of the dissociated steroid RU24858 does not exclude a role for inducible genes in the anti-inflammatory actions of glucocorticoids. Mol Pharmacol 70: 2084-2095. (Pubitemid 44771924)
10. Cho IJ, Kim SG, (2009). A novel mitogen-activated protein kinase phosphatase-1 and glucocorticoid receptor (GR) interacting protein-1-dependent combinatorial mechanism of gene transrepression by GR. Mol Endocrinol 23: 86-99.
11. Clark AR, (2007). Anti-inflammatory functions of glucocorticoid-induced genes. Mol Cell Endocrinol 275: 79-97. (Pubitemid 47259278)
12. Coghlan MJ, Elmore SW, Kort ME, Kym PR, Moore JL, Pratt JK, et al,. (1999). Preparation of glucocorticoid-selective anti-inflammatory agents. Patent WO99041256.
13. De Bosscher K, Haegeman G, Elewaut D, (2010). Targeting inflammation using selective glucocorticoid receptor modulators. Curr Opin Pharmacol 10: 497-504.
14. Diefenbacher M, Sekula S, Heilbock C, Maier JV, Litfin M, van Dam H, et al,. (2008). Restriction to Fos family members of Trip6-dependent coactivation and glucocorticoid receptor-dependent trans-repression of activator protein-1. Mol Endocrinol 22: 1767-1780.
15. Dorfman K, Carrasco D, Gruda M, Ryan C, Lira SA, Bravo R, (1996). Disruption of the erp/mkp-1 gene does not affect mouse development: normal MAP kinase activity in ERP/MKP-1-deficient fibroblasts. Oncogene 13: 925-931. (Pubitemid 26329078)
16. Frijters R, Fleuren W, Toonen EJ, Tuckermann JP, Reichardt HM, Van der Maaden H, et al,. (2010). Prednisolone-induced differential gene expression in mouse liver carrying wild type or a dimerization-defective glucocorticoid receptor. BMC Genomics 11: 359.
17. Furst R, Schroeder T, Eilken HM, Bubik MF, Kiemer AK, Zahler S, et al,. (2007). MAPK phosphatase-1 represents a novel anti-inflammatory target of glucocorticoids in the human endothelium. FASEB J 21: 74-80. (Pubitemid 46052546)
18. Galliher-Beckley AJ, Cidlowski JA, (2009). Emerging roles of glucocorticoid receptor phosphorylation in modulating glucocorticoid hormone action in health and disease. IUBMB Life 61: 979-986.
19. Galliher-Beckley AJ, Williams JG, Collins JB, Cidlowski JA, (2008). Glycogen synthase kinase 3β-mediated serine phosphorylation of the human glucocorticoid receptor redirects gene expression profiles. Mol Cell Biol 28: 7309-7322.
20. Glass CK, Saijo K, (2010). Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat Rev Immunol 10: 365-376.
21. Gupta V, Galante A, Soteropoulos P, Guo S, Wagner BJ, (2005). Global gene profiling reveals novel glucocorticoid induced changes in gene expression of human lens epithelial cells. Mol Vis 11: 1018-1040. (Pubitemid 41672497)
22. Hammer M, Mages J, Dietrich H, Servatius A, Howells N, Cato A, et al,. (2006). Dual specificity phosphatase 1 (DUSP1) regulates a subset of LPS-induced genes and protects mice from lethal endotoxin shock. J Exp Med 203: 15-20. (Pubitemid 43139639)
23. Hillier SG, (2007). Diamonds are forever: the cortisone legacy. J Endocrinol 195: 1-6. (Pubitemid 350055993)
24. Holden NS, Gong W, King EM, Kaur M, Giembycz MA, Newton R, (2007). Potentiation of NF-κB-dependent transcription and inflammatory mediator release by histamine in human airway epitheial cells. Br J Pharmacol 152: 891-902. (Pubitemid 350100496)
25. Hudson AR, Roach SL, Higuchi RI, (2008). Recent developments in the discovery of selective glucocorticoid receptor modulators (SGRMs). Curr Top Med Chem 8: 750-765. (Pubitemid 351982564)
26. Humphrey EL, Williams JH, Davie MW, Marshall MJ, (2006). Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells. Bone 38: 652-661.
27. Issa R, Xie S, Khorasani N, Sukkar M, Adcock IM, Lee KY, et al,. (2007). Corticosteroid inhibition of growth-related oncogene protein-alpha via mitogen-activated kinase phosphatase-1 in airway smooth muscle cells. J Immunol 178: 7366-7375. (Pubitemid 46847464)
28. Janka-Junttila M, Moilanen E, Hasala H, Zhang X, Adcock I, Kankaanranta H, (2006). The glucocorticoid RU24858 does not distinguish between transrepression and transactivation in primary human eosinophils. J Inflamm (Lond) 3: 1 -10.
29. Jaroch S, Lehmann M, Schmees N, Buchmann B, Rehwinkel H, Droescher P, et al,. (2002). Preparation of amido-benzoxazinone/phthalides as non-steroidal inflammation inhibitors. Patent WO02010143.
30. Johansson-Haque K, Palanichamy E, Okret S, (2008). Stimulation of MAPK-phospatase 1 (MKP-1) gene expression by glucocorticoids occurs through a tethering mechanism involving C/EBP. J Mol Endocrinol 41: 239-249.
31. John S, Sabo PJ, Thurman RE, Sung MH, Biddie SC, Johnson TA, et al,. (2011). Chromatin accessibility pre-determines glucocorticoid receptor binding patterns. Nat Genet 43: 264-268.
32. Kang BN, Jude JA, Panettieri RA, Jr, Walseth TF, Kannan MS, (2008). Glucocorticoid regulation of CD38 expression in human airway smooth muscle cells: role of dual specificity phosphatase 1. Am J Physiol Lung Cell Mol Physiol 295: L186-L193.
33. Kassel O, Herrlich P, (2007). Crosstalk between the glucocorticoid receptor and other transcription factors: Molecular aspects. Mol Cell Endocrinol 275: 13-29. (Pubitemid 47259283)
34. King EM, Holden NS, Gong W, Rider CF, Newton R, (2009). Inhibition of NF-kappaB-dependent transcription by MKP-1: transcriptional repression by glucocorticoids occurring via p38 MAPK. J Biol Chem 284: 26803-26815.
35. Kleiman A, Tuckermann JP, (2007). Glucocorticoid receptor action in beneficial and side effects of steroid therapy: lessons from conditional knockout mice. Mol Cell Endocrinol 275: 98-108. (Pubitemid 47259279)
36. Kym PR, Kort ME, Coghlan MJ, Moore JL, Tang R, Ratajczyk JD, et al,. (2003). Nonsteroidal selective glucocorticoid modulators: the effect of C-10 substitution on receptor selectivity and functional potency of 5-allyl-2,5-dihydro-2,2,4-trimethyl-1H-[1]benzopyrano[3,4-f]quinolines. J Med Chem 46: 1016-1030. (Pubitemid 36423148)
37. Lari R, Fleetwood AJ, Kitchener PD, Cook AD, Pavasovic D, Hertzog PJ, et al,. (2007). Macrophage lineage phenotypes and osteoclastogenesis-complexity in the control by GM-CSF and TGFβ. Bone 40: 323-326.
38. Lasa M, Brook M, Saklatvala J, Clark AR, (2001). Dexamethasone destabilizes cyclooxygenase 2 mRNA by inhibiting mitogen-activated protein kinase p38. Mol Cell Biol 21: 771-780. (Pubitemid 32104726)
39. Lasa M, Abraham SM, Boucheron C, Saklatvala J, Clark AR, (2002). Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38. Mol Cell Biol 22: 7802-7811. (Pubitemid 35217291)
40. Li F, Zhang M, Hussain F, Triantaphyllopoulos K, Clark AR, Bhavsar PK, et al,. (2010). Inhibition of p38-MAPK-dependent bronchial contraction after ozone by corticosteroids. Eur Respir J 37: 933-942.
41. Lopez FJ, Ardecky RJ, Bebo B, Benbatoul K, De Grandpre L, Liu S, et al,. (2008). LGD-5552, an antiinflammatory glucocorticoid receptor ligand with reduced side effects, in vivo. Endocrinology 149: 2080-2089. (Pubitemid 351574480)
42. Meijsing SH, Pufall MA, So AY, Bates DL, Chen L, Yamamoto KR, (2009). DNA binding site sequence directs glucocorticoid receptor structure and activity. Science 324: 407-410.
43. Miner JN, Ardecky B, Benbatoul K, Griffiths K, Larson CJ, Mais DE, et al,. (2007). Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile. Proc Natl Acad Sci USA 104: 19244-19249.
44. Newton R, (2000). Molecular mechanisms of glucocorticoid action: what is important? Thorax 55: 603-613. (Pubitemid 30398277)
45. Newton R, Holden NS, (2007). Separating transrepression and transactivation: a distressing divorce for the glucocorticoid receptor? Mol Pharmacol 72: 799-809. (Pubitemid 47481403)
46. Newton R, Leigh R, Giembycz MA, (2010). Pharmacological strategies for improving the efficacy and therapeutic ratio of glucocorticoids in inflammatory lung diseases. Pharmacol Ther 125: 286-327.
47. Owens DM, Keyse SM, (2007). Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 26: 3203-3213. (Pubitemid 46763015)
48. Pfeffer BA, DeWitt CA, Salvador-Silva M, Cavet ME, Lopez FJ, Ward KW, (2010). Reduced myocilin expression in cultured monkey trabecular meshwork cells induced by a selective glucocorticoid receptor agonist: comparison with steroids. Invest Ophthalmol Vis Sci 51: 437-446.
49. Quante T, Ng YC, Ramsay EE, Henness S, Allen JC, Parmentier J, et al,. (2008). Corticosteroids reduce IL-6 in ASM cells via up-regulation of MKP-1. Am J Respir Cell Mol Biol 39: 208-217.
50. Rauch A, Seitz S, Baschant U, Schilling AF, Illing A, Stride B, et al,. (2010). Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab 11: 517-531.
51. Reddy TE, Pauli F, Sprouse RO, Neff NF, Newberry KM, Garabedian MJ, et al,. (2009). Genomic determination of the glucocorticoid response reveals unexpected mechanisms of gene regulation. Genome Res 19: 2163-2171.
52. Schacke H, Docke WD, Asadullah K, (2002). Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 96: 23-43. (Pubitemid 35346616)
53. Schacke H, Schottelius A, Docke WD, Strehlke P, Jaroch S, Schmees N, et al,. (2004). Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA 101: 227-232. (Pubitemid 38084232)
54. Schacke H, Berger M, Rehwinkel H, Asadullah K, (2007). Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol 275: 109-117. (Pubitemid 47259282)
55. Schacke H, Zollner TM, Docke WD, Rehwinkel H, Jaroch S, Skuballa W, et al,. (2009). Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases. Br J Pharmacol 158: 1088-1103.
56. Shafiee A, Bucolo C, Budzynski E, Ward KW, Lopez FJ, (2010). In vivo ocular efficacy profile of BOL-303242-X, a novel selective glucocorticoid receptor agonist, in rabbit models of ocular disease. Invest Ophthalmol Vis Sci 52: 1422-1430.
57. Shipp LE, Lee JV, Yu CY, Pufall M, Zhang P, Scott DK, et al,. (2010). Transcriptional regulation of human dual specificity protein phosphatase 1 (DUSP1) gene by glucocorticoids. PLoS ONE 5: e13754.
58. Smoak K, Cidlowski JA, (2006). Glucocorticoids regulate tristetraprolin synthesis and posttranscriptionally regulate tumor necrosis factor alpha inflammatory signaling. Mol Cell Biol 26: 9126-9135. (Pubitemid 44851967)
59. So AY, Chaivorapol C, Bolton EC, Li H, Yamamoto KR, (2007). Determinants of cell- and gene-specific transcriptional regulation by the glucocorticoid receptor. PLoS Genet 3: e94.
60. Tchen CR, Martins JR, Paktiawal N, Perelli R, Saklatvala J, Clark AR, (2010). Glucocorticoid regulation of mouse and human dual specificity phosphatase 1 (DUSP1) genes: unusual cis-acting elements and unexpected evolutionary divergence. J Biol Chem 285: 2642-2652.
61. Tuckermann JP, Reichardt HM, Arribas R, Richter KH, Schutz G, Angel P, (1999). The DNA binding-independent function of the glucocorticoid receptor mediates repression of AP-1-dependent genes in skin. J Cell Biol 147: 1365-1370. (Pubitemid 30027391)
62. Tuckermann JP, Kleiman A, McPherson KG, Reichardt HM, (2005). Molecular mechanisms of glucocorticoids in the control of inflammation and lymphocyte apoptosis. Crit Rev Clin Lab Sci 42: 71-104. (Pubitemid 41656710)
63. Vayssiere BM, Dupont S, Choquart A, Petit F, Garcia T, Marchandeau C, et al,. (1997). Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol Endocrinol 11: 1245-1255. (Pubitemid 28041332)
64. Wang X, Nelin LD, Kuhlman JR, Meng X, Welty SE, Liu Y, (2008). The role of MAP kinase phosphatase-1 in the protective mechanism of dexamethasone against endotoxemia. Life Sci 83: 671-680.
65. Zhang JZ, Cavet ME, VanderMeid KR, Salvador-Silva M, Lopez FJ, Ward KW, (2009). BOL-303242-X, a novel selective glucocorticoid receptor agonist, with full anti-inflammatory properties in human ocular cells. Mol Vis 15: 2606-2616.